Cargando…
Mesenteric inflammatory myofibroblastic tumors
Inflammatory myofibroblastic tumors (IMTs), also known as inflammatory pseudotumors and inflammatory fibrosarcomas, are uncommon mesenchymal tumors composed of myofibroblastic spindle cells admixed with lymphocytes, plasma cells and eosinophils. Once thought to be reactive, these lesions are now con...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290004/ https://www.ncbi.nlm.nih.gov/pubmed/25608706 |
_version_ | 1782352178939166720 |
---|---|
author | Chaudhary, Poras |
author_facet | Chaudhary, Poras |
author_sort | Chaudhary, Poras |
collection | PubMed |
description | Inflammatory myofibroblastic tumors (IMTs), also known as inflammatory pseudotumors and inflammatory fibrosarcomas, are uncommon mesenchymal tumors composed of myofibroblastic spindle cells admixed with lymphocytes, plasma cells and eosinophils. Once thought to be reactive, these lesions are now considered to be neoplastic. These tumors can occur throughout the body, most commonly in the lung, mesentery and omentum. Patients commonly present with painless abdominal mass or with intestinal obstruction. IMTs may be multicentric, have a high local recurrence rate and may metastasize in rare cases. The lesions show wide variability in their histologic features and cellularity, and marked inflammatory infiltration, predominantly of plasmatocytes and lymphocytes, and occasionally neutrophils and eosinophils. Anaplastic lymphoma kinase (ALK) rearrangements and/or ALK1 and p80 immunoreactivity are reported in 33-67% of the tumors. Owing to the rarity of these lesions, there are no specific imaging findings that distinguish IMTs from other mesenteric masses. Complete surgical resection is the treatment of choice. Local recurrence rates are high, and re-excision is the preferred therapy for local recurrences. ALK-positive tumors show good response to ALK inhibitors. Current knowledge and comprehensive review of the available literature on IMTs is herein presented. |
format | Online Article Text |
id | pubmed-4290004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-42900042015-01-21 Mesenteric inflammatory myofibroblastic tumors Chaudhary, Poras Ann Gastroenterol Review Inflammatory myofibroblastic tumors (IMTs), also known as inflammatory pseudotumors and inflammatory fibrosarcomas, are uncommon mesenchymal tumors composed of myofibroblastic spindle cells admixed with lymphocytes, plasma cells and eosinophils. Once thought to be reactive, these lesions are now considered to be neoplastic. These tumors can occur throughout the body, most commonly in the lung, mesentery and omentum. Patients commonly present with painless abdominal mass or with intestinal obstruction. IMTs may be multicentric, have a high local recurrence rate and may metastasize in rare cases. The lesions show wide variability in their histologic features and cellularity, and marked inflammatory infiltration, predominantly of plasmatocytes and lymphocytes, and occasionally neutrophils and eosinophils. Anaplastic lymphoma kinase (ALK) rearrangements and/or ALK1 and p80 immunoreactivity are reported in 33-67% of the tumors. Owing to the rarity of these lesions, there are no specific imaging findings that distinguish IMTs from other mesenteric masses. Complete surgical resection is the treatment of choice. Local recurrence rates are high, and re-excision is the preferred therapy for local recurrences. ALK-positive tumors show good response to ALK inhibitors. Current knowledge and comprehensive review of the available literature on IMTs is herein presented. Hellenic Society of Gastroenterology 2015 /pmc/articles/PMC4290004/ /pubmed/25608706 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Chaudhary, Poras Mesenteric inflammatory myofibroblastic tumors |
title | Mesenteric inflammatory myofibroblastic tumors |
title_full | Mesenteric inflammatory myofibroblastic tumors |
title_fullStr | Mesenteric inflammatory myofibroblastic tumors |
title_full_unstemmed | Mesenteric inflammatory myofibroblastic tumors |
title_short | Mesenteric inflammatory myofibroblastic tumors |
title_sort | mesenteric inflammatory myofibroblastic tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290004/ https://www.ncbi.nlm.nih.gov/pubmed/25608706 |
work_keys_str_mv | AT chaudharyporas mesentericinflammatorymyofibroblastictumors |